Sermorelin

Prompts your pituitary to release its own growth hormone in natural pulses, rather than injecting GH itself. It raises how much GH each pulse puts out — the same GHRH lever CJC-1295 pulls. People run it for sleep, recovery, and the slow body-recomposition of gently raised GH/IGF-1, and reach for it as the more conservative, better-documented option in the GH-secretagogue family.

It’s the rare peptide here with a real regulatory past: a synthetic GHRH(1-29) that was an approved pharmaceutical, used both as a diagnostic agent — give it, then measure whether the pituitary answers, which separates a pituitary problem from a hypothalamic one — and as a pediatric growth-failure treatment, before the maker discontinued it in 2008 for commercial reasons. That history is why it’s the most studied molecule in this corner. The catch: it’s short-acting (an ~11–12 minute half-life), so like CJC-1295 without DAC it’s pinned at night and usually paired with a secretagogue rather than run as a constant elevation.

A GHRH analog: it binds the growth-hormone-releasing-hormone receptor in the pituitary and increases the GH released per pulse. It doesn’t create the pulses — it amplifies them and works with your own feedback loops, which is the community’s argument for it being more physiological than injecting GH directly. Because it’s the bare 1-29 fragment with no half-life-extending modification, it clears in minutes, which is exactly why it’s dosed at bedtime to ride the natural overnight GH surge and why it’s stacked with a GHRP that triggers the pulse itself.

Generally mild and mostly tied to the GH bump or the injection itself: flushing or a head-rush right after the shot, injection-site redness, occasional headache, and the hand tingling/numbness that tracks with raised GH. As with every GH-axis peptide, the real consideration isn’t an acute side effect — it’s that chronically raising GH/IGF-1 is not advisable for anyone with cancer concerns. Its longer regulatory track record means its tolerability is better characterized than most peptides on this site, but that record was built on diagnostic and pediatric use, not the nightly anti-aging protocol people actually run.

The natural pairing is a GHRP-type secretagogue — Ipamorelin most often — for the same reason CJC-1295 is: the GHRH analog raises how much GH each pulse releases, the secretagogue triggers the pulse and lifts the somatostatin brake. They pull different levers, so the combination does more than either alone. In practice, though, CJC-1295 has largely displaced sermorelin as the GHRH half of that stack, since CJC is longer-acting; sermorelin is the older, shorter, more clinically-vetted alternative.